Updated treatment of castration-resistant prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 1136-1140, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-319552
ABSTRACT
Most prostate cancer cases ultimately relapse after a period of initial response to castration therapy and progress to intractable castration-resistant prostate cancer (CRPC). Hardly any therapeutic options currently used can improve the 2- to 3-year survival of the patient. Recently, some new drugs for the treatment of CRPC through various action mechanisms have been approved, and others are in the advanced stage of clinical trial. This review provides an overview of these new therapeutic agents.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Neoplasms
/
General Surgery
/
Orchiectomy
/
Mortality
/
Therapeutic Uses
/
Drug Therapy
/
Prostatic Neoplasms, Castration-Resistant
/
Neoplasm Recurrence, Local
/
Antineoplastic Agents
Type of study:
Prognostic study
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS